towards improved death receptor targeted therapy for ... - TI Pharma

Reference List
TRAIL‐induced migration and invasion
1. Field JK, Duffy SW. Lung cancer screening: the way forward. Br J Cancer 2008; 99(4):557‐
562.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5):277‐
300.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359(13):1367‐1380.
4. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene
2010; 29(34):4752‐4765.
5. Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL receptor
targeting therapies for non‐small cell lung cancer: current status and perspectives. Drug
Resist Updat 2010; 13(1‐2):2‐15.
6. Newsom‐Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis
2009; 14(4):607‐623.
7. Jin Z, El‐Deiry WS. Distinct signaling pathways in T. Mol Cell Biol 2006; 26(21):8136‐8148.
8. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D et al. Molecular
determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor‐related
apoptosis‐inducing ligand. J Biol Chem 2005; 280(49):40599‐40608.
9. Declercq W, Vanden BT, Vandenabeele P. RIP kinases at the crossroads of cell death and
survival. Cell 2009; 138(2):229‐232.
10. Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem
Sci 2005; 30(3):151‐159.
11. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF et al.
Oncogenic K‐Ras turns death receptors into metastasis‐promoting receptors in human and
mouse colorectal cancer cells. Gastroenterology 2010; 138(7):2357‐2367.
12. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D et al. TRAIL
promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006;
25(56):7434‐7439.
13. Bijnsdorp IV, Capriotti F, Kruyt FA, Losekoot N, Fukushima M, Griffioen AW et al.
Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and
invasion by the secretion of angiogenic factors. Br J Cancer 2011; 104(7):1185‐1192.
14. Yarrow JC, Perlman ZE, Westwood NJ, Mitchison TJ. A high‐throughput cell migration assay
using scratch wound healing, a comparison of image‐based readout methods. BMC
Biotechnol 2004; 4:21.
15. Parikh K, Peppelenbosch MP, Ritsema T. Kinome profiling using peptide arrays in
eukaryotic cells. Methods Mol Biol 2009; 527:269‐80, x.
16. van Baal JW, Diks SH, Wanders RJ, Rygiel AM, Milano F, Joore J et al. Comparison of
kinome profiles of Barrett's esophagus with normal squamous esophagus and normal
gastric cardia. Cancer Res 2006; 66(24):11605‐11612.
17. Fuhler GM, Diks SH, Peppelenbosch MP, Kerr WG. Widespread deregulation of
phosphorylation‐based signaling pathways in multiple myeloma cells: opportunities for
therapeutic intervention. Mol Med 2011; 17(7‐8):790‐798.
18. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus‐
mediated RNA interference. Cancer Cell 2002; 2(3):243‐247.
19. van Leuken R, Clijsters L, van ZW, Lim D, Yao X, Wolthuis RM et al. Polo‐like kinase‐1
controls Aurora A destruction by activating APC/C‐Cdh1. PLoS One 2009; 4(4):e5282.
20. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor
receptor inhibitors in non‐small cell lung cancer cells: limited antiproliferative effects and
absence of apoptosis associated with persistent activity of extracellular signal‐regulated
kinase or Akt kinase pathways. Clin Cancer Res 2003; 9(6):2316‐2326.
21. Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M et al. Rapid and
efficient cancer cell killing mediated by high‐affinity death receptor homotrimerizing TRAIL
‐ 79 ‐